AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (2 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Major roles of the circadian clock in cancer

Chen Huang1,*, Chenliang Zhang2,*, Yubin Cao3, Jian Li4, Feng Bi1 ( )
Department of Abdominal Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610000, China
Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610000, China
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610000, China
West China School of Medicine, Sichuan University, Chengdu 610000, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Circadian rhythms are natural rhythms that widely exist in all creatures, and regulate the processes and physiological functions of various biochemical reactions. The circadian clock is critical for cancer occurrence and progression. Its function is regulated by metabolic activities, and the expression and transcription of various genes. This review summarizes the composition of the circadian clock; the biological basis for its function; its relationship with, and mechanisms in, cancer; its various functions in different cancers; the effects of anti-tumor treatment; and potential therapeutic targets. Research in this area is expected to advance understanding of circadian locomotor output cycles kaput (CLOCK) and brain and muscle ARNT-like protein 1 (BMAL1) in tumor diseases, and contribute to the development of new anti-tumor treatment strategies.

Keywords

Circadian clockcancertumor therapyoncologyBMAL1

Electronic Supplementary Material

Download File(s)
cbm-20-1-1_ESM.pdf (2.9 MB)

References

1

Shafi AA, Knudsen KE. Cancer and the circadian clock. Cancer Res. 2019; 79: 3806-14.
Crossref Google Scholar
2

Ouyang Y, Andersson CR, Kondo T, Golden SS, Johnson CH. Resonating circadian clocks enhance fitness in cyanobacteria. Proc Natl Acad Sci U S A. 1998; 95: 8660-4.
Crossref Google Scholar
3

Turek FW. Circadian clocks: not your grandfather’s clock. Science. 2016; 354: 992-3.
Crossref Google Scholar
4

Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012; 35: 445-62.
Crossref Google Scholar
5

Sancar A, van Gelder RN. Clocks, cancer, and chronochemotherapy. Science. 2021; 371: eabb0738.
Crossref Google Scholar
6

Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. Trends Cell Biol. 2014; 24: 90-9.
Crossref Google Scholar
7

Patke A, Young MW, Axelrod S. Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol. 2020; 21: 67-84.
Crossref Google Scholar
8

Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002; 418: 935-41.
Crossref Google Scholar
9

Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003; 4: 649-61.
Crossref Google Scholar
10

Cederroth CR, Albrecht U, Bass J, Brown SA, Dyhrfjeld-Johnsen J, Gachon F, et al. Medicine in the fourth dimension. Cell Metab. 2019; 30: 238-50.
Crossref Google Scholar
11

Lubov JE, Cvammen W, Kemp MG. The impact of the circadian clock on skin physiology and cancer development. Int J Mol Sci. 2021; 22: 6112.
Crossref Google Scholar
12

Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, et al. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell. 1999; 98: 193-205.
Crossref Google Scholar
13

Griffin EA, Staknis D, Weitz CJ. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science. 1999; 286: 768-71.
Crossref Google Scholar
14

Sangoram AM, Saez L, Antoch MP, Gekakis N, Staknis D, Whiteley A, et al. Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCKBMAL1-induced transcription. Neuron. 1998; 21: 1101-13.
Crossref Google Scholar
15

Narasimamurthy R, Virshup DM. The phosphorylation switch that regulates ticking of the circadian clock. Mol Cell 2021; 81: 1133-46.
Crossref Google Scholar
16

Kondratov RV, Chernov MV, Kondratova AA, Gorbacheva VY, Gudkov AV, Antoch MP. BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev. 2003; 17: 1921-32.
Crossref Google Scholar
17

Kondratov RV, Shamanna RK, Kondratova AA, Gorbacheva VY, Antoch MP. Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation. FASEB J. 2006; 20: 530-2.
Crossref Google Scholar
18

Xu Y, Padiath QS, Shapiro RE, Jones CR, Wu SC, Saigoh N, et al. Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature. 2005; 434: 640-4.
Crossref Google Scholar
19

Etchegaray JP, Machida KK, Noton E, Constance CM, Dallmann R, Di Napoli MN, et al. Casein kinase 1 delta regulates the pace of the mammalian circadian clock. Mol Cell Biol. 2009; 29: 3853-66.
Crossref Google Scholar
20

Philpott JM, Narasimamurthy R, Ricci CG, Freeberg AM, Hunt SR, Yee LE, et al. Casein kinase 1 dynamics underlie substrate selectivity and the PER2 circadian phosphoswitch. Elife. 2020; 9: e52343.
Crossref Google Scholar
21

Green CB. Circadian posttranscriptional regulatory mechanisms in mammals. Cold Spring Harb Perspect Biol. 2018; 10: a030692.
Crossref Google Scholar
22

Shilts J, Chen G, Hughey JJ. Evidence for widespread dysregulation of circadian clock progression in human cancer. PeerJ. 2018; 6: e4327.
Crossref Google Scholar
23

Shostak A, Ruppert B, Ha N, Bruns P, Toprak UH, Eils R, et al. MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation. Nat Commun. 2016; 7: 11807.
Crossref Google Scholar
24

Huber AL, Papp SJ, Chan AB, Henriksson E, Jordan SD, Kriebs A, et al. CRY2 and FBXL3 cooperatively degrade c-MYC. Mol Cell. 2016; 64: 774-89.
Crossref Google Scholar
25

Aviram R, Manella G, Kopelman N, Neufeld-Cohen A, Zwighaft Z, Elimelech M, et al. Lipidomics analyses reveal temporal and spatial lipid organization and uncover daily oscillations in intracellular organelles. Mol Cell 2016; 62: 636-48.
Crossref Google Scholar
26

Blask DE, Dauchy RT, Dauchy EM, Mao L, Hill SM, Greene MW, et al. Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS One. 2014; 9: e102776.
Crossref Google Scholar
27

Gamble KL, Berry R, Frank SJ, Young ME. Circadian clock control of endocrine factors. Nat Rev Endocrinol. 2014; 10: 466-75.
Crossref Google Scholar
28

Greene MW. Circadian rhythms and tumor growth. Cancer Lett. 2012; 318: 115-23.
Crossref Google Scholar
29

He W, Holtkamp S, Hergenhan SM, Kraus K, de Juan A, Weber J, et al. Circadian expression of migratory factors establishes lineagespecific signatures that guide the homing of leukocyte subsets to tissues. Immunity. 2018; 49: 1175-90.e7.
Crossref Google Scholar
30

Aiello I, Fedele MLM, Román F, Marpegan L, Caldart C, Chiesa JJ, et al. Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci Adv. 2020; 6: eaaz4530.
Crossref Google Scholar
31

Hadadi E, Taylor W, Li XM, Aslan Y, Villote M, Rivière J, et al. Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun. 2020; 11: 3193.
Crossref Google Scholar
32

Wu Y, Tao B, Zhang T, Fan Y, Mao R. Pan-cancer analysis reveals disrupted circadian clock associates with T cell exhaustion. Front Immunol. 2019; 10: 2451.
Crossref Google Scholar
33

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018; 48: 812-30.e14.
Crossref Google Scholar
34

Xie Y, Tang Q, Chen G, Xie M, Yu S, Zhao J, et al. New insights into the circadian rhythm and its related diseases. Front Physiol. 2019; 10: 682.
Crossref Google Scholar
35

Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet. Neurol. 2019; 18: 307-18.
Crossref Google Scholar
36

Kinouchi K, Sassone-Corsi P. Metabolic rivalry: circadian homeostasis and tumorigenesis. Nat Rev Cancer. 2020; 20: 645-61.
Crossref Google Scholar
37

Schibler U, Gotic I, Saini C, Gos P, Curie T, Emmenegger Y, et al. Clock-talk: interactions between central and peripheral circadian oscillators in mammals. Cold Spring Harb Symp Quant Biol. 2015; 80: 223-32.
Crossref Google Scholar
38

Cox KH, Takahashi JS. Circadian clock genes and the transcriptional architecture of the clock mechanism. J Mol Endocrinol. 2019; 63: R93-102.
Crossref Google Scholar
39

Finger AM, Dibner C, Kramer A. Coupled network of the circadian clocks: a driving force of rhythmic physiology. FEBS Lett. 2020; 594: 2734-69.
Crossref Google Scholar
40

Numata M, Hirano A, Yamamoto Y, Yasuda M, Miura N, Sayama K, et al. Metastasis of breast cancer promoted by circadian rhythm disruption due to light/dark shift and its prevention by dietary quercetin in mice. J Circadian Rhythms. 2021; 19: 2.
Crossref Google Scholar
41

Ha NH, Long J, Cai Q, Shu XO, Hunter KW. The circadian rhythm gene Arntl2 is a metastasis susceptibility gene for estrogen receptornegative breast cancer. PLoS Genetics. 2016; 12: e1006267.
Crossref Google Scholar
42

Chen J, Liu A, Lin Z, Wang B, Chai X, Chen S, et al. Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signaling. Cancer Lett. 2020; 482: 56-71.
Crossref Google Scholar
43

Wang Y, Sun N, Lu C, Bei Y, Qian R, Hua L. Upregulation of circadian gene ‘hClock’ contribution to metastasis of colorectal cancer. Int J Oncol. 2017; 50: 2191-9.
Crossref Google Scholar
44

Koritala BSC, Porter KI, Arshad OA, Gajula RP, Mitchell HD, Arman T, et al. Night shift schedule causes circadian dysregulation of DNA repair genes and elevated DNA damage in humans. J Pineal Res. 2021; 70: e12726.
Crossref Google Scholar
45

Dun A, Zhao X, Jin X, Wei T, Gao X, Wang Y, et al. Association between night-shift work and cancer risk: updated systematic review and meta-analysis. Front Oncol. 2020; 10: 1006.
Crossref Google Scholar
46

Srour B, Plancoulaine S, Andreeva VA, Fassier P, Julia C, Galan P, et al. Circadian nutritional behaviours and cancer risk: new insights from the NutriNet-santé prospective cohort study: disclaimers. Int J Cancer. 2018; 143: 2369-79.
Crossref Google Scholar
47

Lou X, Wang H, Tu Y, Tan W, Jiang C, Sun J, et al. Alterations of sleep quality and circadian rhythm genes expression in elderly thyroid nodule patients and risks associated with thyroid malignancy. Sci Rep. 2021; 11: 13682.
Crossref Google Scholar
48

Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev. 2006; 20: 1868-73.
Crossref Google Scholar
49

Yu EA, Weaver DR. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging. 2011; 3: 479-93.
Crossref Google Scholar
50

Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, et al. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 2016; 24: 324-31.
Crossref Google Scholar
51

Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019; 5: 475-94.
Crossref Google Scholar
52

Zhou L, Luo Z, Li Z, Huang Q. Circadian clock is associated with tumor microenvironment in kidney renal clear cell carcinoma. Aging. 2020; 12: 14620-32.
Crossref Google Scholar
53

Yang Y, Yuan G, Xie H, Wei T, Zhu D, Cui J, et al. Circadian clock associates with tumor microenvironment in thoracic cancers. Aging. 2019; 11: 11814-28.
Crossref Google Scholar
54

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016; 23: 27-47.
Crossref Google Scholar
55

Chen WD, Wen MS, Shie SS, Lo YL, Wo HT, Wang CC, et al. The circadian rhythm controls telomeres and telomerase activity. Biochem Biophys Res Commun. 2014; 451: 408-14.
Crossref Google Scholar
56

Ruan W, Yuan X, Eltzschig HK. Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021; 20: 287-307.
Crossref Google Scholar
57

Chen P, Hsu WH, Han J, Xia Y, DePinho RA. Cancer stemness meets immunity: from mechanism to therapy. Cell Rep. 2021; 34: 108597.
Crossref Google Scholar
58

Chen P, Hsu WH, Chang A, Tan Z, Lan Z, Zhou A, et al. Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov. 2020; 10: 371-81.
Crossref Google Scholar
59

Dong Z, Zhang G, Qu M, Gimple RC, Wu Q, Qiu Z, et al. Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. 2019; 9: 1556-73.
Crossref Google Scholar
60

Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, et al. Core circadian clock genes regulate leukemia stem cells in AML. Cell. 2016; 165: 303-16.
Crossref Google Scholar
61

Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, et al. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis. 2015; 36 Suppl 1: S184-202.
Crossref Google Scholar
62

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020; 39: 204.
Crossref Google Scholar
63

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
Crossref Google Scholar
64

Shalapour S, Karin M. Pas de deux: control of anti-tumor immunity by cancer-associated inflammation. Immunity. 2019; 51: 15-26.
Crossref Google Scholar
65

Ramos CA, Ouyang C, Qi Y, Chung Y, Cheng CT, LaBarge MA, et al. A non-canonical function of BMAL1 metabolically limits obesitypromoted triple-negative breast cancer. iScience. 2020; 23: 100839.
Crossref Google Scholar
66

Matsunaga N, Ogino T, Hara Y, Tanaka T, Koyanagi S, Ohdo S. Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Res. 2018; 78: 3698-708.
Crossref Google Scholar
67

Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R, et al. A pan-ALDH1A inhibitor induces necroptosis in ovarian cancer stem-like cells. Cell Rep. 2019; 26: 3061-3075.e6.
Crossref Google Scholar
68

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-60.
Crossref Google Scholar
69

Avau B, Carbone F, Tack J, Depoortere I. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential. Neurogastroenterol Motil. 2013; 25: 720-32.
Crossref Google Scholar
70

Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab. 2015; 4: 437-60.
Crossref Google Scholar
71

Waseem T, Javaid Ur R, Ahmad F, Azam M, Qureshi MA. Role of ghrelin axis in colorectal cancer: a novel association. Peptides. 2008; 29: 1369-76.
Crossref Google Scholar
72

Murata M, Okimura Y, Iida K, Matsumoto M, Sowa H, Kaji H, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem. 2002; 277: 5667-74.
Crossref Google Scholar
73

De Vriese C, Grégoire F, De Neef P, Robberecht P, Delporte C. Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. Endocrinology. 2005; 146: 1514-22.
Crossref Google Scholar
74

Fung JNT, Seim I, Wang D, Obermair A, Chopin LK, Chen C. Expression and in vitro functions of the ghrelin axis in endometrial cancer. Horm Cancer. 2010; 1: 245-55.
Crossref Google Scholar
75

Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW, et al. Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun. 2003; 309: 464-68.
Crossref Google Scholar
76

Lien GS, Lin CH, Yang YL, Wu MS, Chen BC. Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways. Eur J Pharmacol. 2016; 776: 124-31.
Crossref Google Scholar
77

Kraus D, Reckenbeil J, Wenghoefer M, Stark H, Frentzen M, Allam JP, et al. Ghrelin promotes oral tumor cell proliferation by modifying GLUT1 expression. Cell Mol Life Sci. 2016; 73: 1287-99.
Crossref Google Scholar
78

Díaz-Lezama N, Hernández-Elvira M, Sandoval A, Monroy A, Felix R, Monjaraz E. Ghrelin inhibits proliferation and increases T-type Ca2+ channel expression in PC-3 human prostate carcinoma cells. Biochem Biophys Res Commun. 2010; 403: 24-9.
Crossref Google Scholar
79

Yeh AH, Jeffery PL, Duncan RP, Herington AC, Chopin LK. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res. 2005; 11: 8295-303.
Crossref Google Scholar
80

Segers A, Desmet L, Sun S, Verbeke K, Tack J, Depoortere I. Nighttime feeding of Bmal1-/- mice restores SCFA rhythms and their effect on ghrelin. J Endocrinol. 2020; 245: 155-64.
Crossref Google Scholar
81

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001; 50: 1714-9.
Crossref Google Scholar
82

Bodosi B, Gardi J, Hajdu I, Szentirmai E, Obal F, Krueger JM. Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R1071-9.
Crossref Google Scholar
83

Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A. 2004; 101: 10434-9.
Crossref Google Scholar
84

Laermans J, Vancleef L, Tack J, Depoortere I. Role of the clock gene Bmal1 and the gastric ghrelin-secreting cell in the circadian regulation of the ghrelin-GOAT system. Sci Rep. 2015; 5: 16748.
Crossref Google Scholar
85

Diehl JA, Fuchs SY, Koumenis C. The cell biology of the unfolded protein response. Gastroenterology. 2011; 141: 38-41.
Crossref Google Scholar
86

Bu Y, Yoshida A, Chitnis N, Altman BJ, Tameire F, Oran A, et al. A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol. 2018; 20: 104-15.
Crossref Google Scholar
87

Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest. 2012; 122: 4621-34.
Crossref Google Scholar
88

Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, et al. HIF-1alpha is essential for myeloid cellmediated inflammation. Cell. 2003; 112: 645-57.
Crossref Google Scholar
89

Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014; 2: 3.
Crossref Google Scholar
90

Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxiainducible factor 1. J Biol Chem. 1994; 269: 23757-63.
Crossref Google Scholar
91

Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010; 70: 7465-75.
Crossref Google Scholar
92

Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. Inhibition of arginase by CB-1158 blocks myeloid cellmediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017; 5: 101.
Crossref Google Scholar
93

Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science. 2013; 341: 1483-8.
Crossref Google Scholar
94

Alexander RK, Liou YH, Knudsen NH, Starost KA, Xu C, Hyde AL, et al. Bmal1 integrates mitochondrial metabolism and macrophage activation. ELife. 2020; 9: e54090.
Crossref Google Scholar
95

DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet (London, England). 2003; 361: 955-64.
Crossref Google Scholar
96

Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.
Crossref Google Scholar
97

Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003; 17: 1115-29.
Crossref Google Scholar
98

Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6: 635-45.
Crossref Google Scholar
99

Larsson LG, Henriksson MA. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010; 316: 1429-37.
Crossref Google Scholar
100

Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah SY, Stine ZE, Walton ZE, et al. MYC disrupts the circadian clock and metabolism in cancer cells. Cell Metab. 2015; 22: 1009-19.
Crossref Google Scholar
101

Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006; 22: 375-82.
Crossref Google Scholar
102

Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 2006; 97: 589-96.
Crossref Google Scholar
103

Yang X, Wood PA, Ansell CM, Quiton DFT, Oh EY, Du-Quiton J, et al. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009; 26: 1323-39.
Crossref Google Scholar
104

Repouskou A, Prombona A. c-MYC targets the central oscillator gene Per1 and is regulated by the circadian clock at the posttranscriptional level. Biochim Biophys Acta. 2016; 1859: 541-52.
Crossref Google Scholar
105

O’Connor K, Chen M. Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases. 2013; 4: 141-7.
Crossref Google Scholar
106

Chiba S, Enami T, Ogawa S, Sakata-Yanagimoto M. G17V RHOA: Genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells. Small GTPases. 2015; 6: 100-3.
Crossref Google Scholar
107

Nomikou E, Stournaras C, Kardassis D. Functional analysis of the promoters of the small GTPases RhoA and RhoB in embryonic stem cells. Biochem Biophys Res Commun. 2017; 491: 754-9.
Crossref Google Scholar
108

Ma TJ, Zhang ZW, Lu YL, Zhang YY, Tao DC, Liu YQ, et al. CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells. Exp Mol Med. 2018; 50: 1-50.
Crossref Google Scholar
109

Ramanathan C, Kathale ND, Liu D, Lee C, Freeman DA, Hogenesch JB, et al. mTOR signaling regulates central and peripheral circadian clock function. PLoS Genet. 2018; 14: e1007369.
Crossref Google Scholar
110

Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21: 656-64.
Crossref Google Scholar
111

Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007; 13: 433-42.
Crossref Google Scholar
112

Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019; 59: 125-32.
Crossref Google Scholar
113

Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8: 774-85.
Crossref Google Scholar
114

Lee Y, Kim EK. AMP-activated protein kinase as a key molecular link between metabolism and clockwork. Exp Mol Med. 2013; 45: e33.
Crossref Google Scholar
115

Um JH, Yang S, Yamazaki S, Kang H, Viollet B, Foretz M, et al. Activation of 5’-AMP-activated kinase with diabetes drug metformin induces casein kinase Iepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J Biol Chem. 2007; 282: 20794-8.
Crossref Google Scholar
116

Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 2013; 73: 2929-35.
Crossref Google Scholar
117

Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol. 2017; 45: 31-7.
Crossref Google Scholar
118

Li Q, Xia D, Wang Z, Liu B, Zhang J, Peng P, et al. Circadian rhythm gene PER3 negatively regulates stemness of prostate cancer stem cells via WNT/β-catenin signaling in tumor microenvironment. Front Cell Dev Biol. 2021; 9: 656981.
Crossref Google Scholar
119

Maiese K. Moving to the rhythm with clock (Circadian) genes, autophagy, mTOR, and SIRT1 in degenerative disease and cancer. Curr Neurovasc Res. 2017; 14: 299-304.
Crossref Google Scholar
120

Okazaki F, Matsunaga N, Okazaki H, Azuma H, Hamamura K, Tsuruta A, et al. Circadian clock in a mouse colon tumor regulates intracellular iron levels to promote tumor progression. J Biol Chem. 2016; 291: 7017-28.
Crossref Google Scholar
121

Shen Y, Endale M, Wang W, Morris AR, Francey LJ, Harold RL, et al. NF-κB modifies the mammalian circadian clock through interaction with the core clock protein BMAL1. PLoS Genet. 2021; 17: e1009933.
Crossref Google Scholar
122

Kubra S, Zhang H, Si Y, Gao X, Wang T, Pan L, et al. REGγ regulates circadian clock by modulating BMAL1 protein stability. Cell Death Discov. 2021; 7: 335.
Crossref Google Scholar
123

Moreno-Smith M, Milazzo G, Tao L, Fekry B, Zhu B, Mohammad MA, et al. Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021; 12: 4006.
Crossref Google Scholar
124

Jiang W, Zhao S, Jiang X, Zhang E, Hu G, Hu B, et al. The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway. Cancer Lett. 2016; 371: 314-25.
Crossref Google Scholar
125

Liu L, Liao JZ, He XX, Li PY. The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget. 2017; 8: 57707-22.
Crossref Google Scholar
126

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
Crossref Google Scholar
127
World Health Organization, Projections of Mortality and Causes of Death, 2016 to 2060. Geneva, Switzerland: World Health Organization; 2020.
128

Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015; 13: 2140-51.
Crossref Google Scholar
129

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 Suppl 1): S35-50.
Crossref Google Scholar
130

Molina-Aguilar C, Guerrero-Carrillo MdJ, Espinosa-Aguirre JJ, Olguin-Reyes S, Castro-Belio T, Vázquez-Martínez O, et al. Time-caloric restriction inhibits the neoplastic transformation of cirrhotic liver in rats treated with diethylnitrosamine. Carcinogenesis. 2017; 38: 847-58.
Crossref Google Scholar
131

Krizkova S, Kepinska M, Emri G, Rodrigo MAM, Tmejova K, Nerudova D, et al. Microarray analysis of metallothioneins in human diseases--A review. J Pharm Biomed Anal, 2016; 117: 464-73.
Crossref Google Scholar
132

Fujie T, Segawa Y, Yoshida E, Kimura T, Fujiwara Y, Yamamoto C, et al. Induction of metallothionein isoforms by copper diethyldithiocarbamate in cultured vascular endothelial cells. J Toxicol Sci. 2016; 41: 225-32.
Crossref Google Scholar
133

Klaassen CD, Liu J, Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 1999; 39: 267-94.
Crossref Google Scholar
134

Li H, Lu YF, Chen H, Liu J. Dysregulation of metallothionein and circadian genes in human hepatocellular carcinoma. Chronobiol Int. 2017; 34: 192-202.
Crossref Google Scholar
135

Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015; 22: R183-204.
Crossref Google Scholar
136

Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, et al. Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017; 18: 843.
Crossref Google Scholar
137

Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017; 8: 39896-921.
Crossref Google Scholar
138

Sánchez DI, González-Fernández B, Crespo I, San-Miguel B, Álvarez M, González-Gallego J, et al. Melatonin modulates dysregulated circadian clocks in mice with diethylnitrosamineinduced hepatocellular carcinoma. J Pineal Res. 2018; 65: e12506.
Crossref Google Scholar
139

Sladek FM, Zhong WM, Lai E, Darnell JE. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 1990; 4: 2353-65.
Crossref Google Scholar
140

Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, et al. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A. 2006; 103: 8419-24.
Crossref Google Scholar
141

Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012; 287: 7345-56.
Crossref Google Scholar
142

Chellappa K, Deol P, Evans JR, Vuong LM, Chen G, Briançon N, et al. Opposing roles of nuclear receptor HNF4α isoforms in colitis and colitis-associated colon cancer. ELife. 2016; 5: e10903.
Crossref Google Scholar
143

Walesky C, Apte U. Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer. Gene Expr. 2015; 16: 101-8.
Crossref Google Scholar
144

Vuong LM, Chellappa K, Dhahbi JM, Deans JR, Fang B, Bolotin E, et al. Differential effects of hepatocyte nuclear factor 4α isoforms on tumor growth and T-cell factor 4/AP-1 interactions in human colorectal cancer cells. Mol Cell Biol. 2015; 35: 3471-90.
Crossref Google Scholar
145

Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, et al. Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res. 2010; 70: 7640-51.
Crossref Google Scholar
146

Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011; 147: 1233-47.
Crossref Google Scholar
147

Walesky C, Edwards G, Borude P, Gunewardena S, O’Neil M, Yoo B, et al. Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 2013; 57: 2480-90.
Crossref Google Scholar
148

Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol. 2006; 208: 662-72.
Crossref Google Scholar
149

Chellappa K, Jankova L, Schnabl JM, Pan S, Brelivet Y, Fung CLS, et al. Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. Proc Natl Acad Sci U S A. 2012; 109: 2302-7.
Crossref Google Scholar
150

Fekry B, Ribas-Latre A, Baumgartner C, Deans JR, Kwok C, Patel P, et al. Incompatibility of the circadian protein BMAL1 and HNF4α in hepatocellular carcinoma. Nat Commun. 2018; 9: 4349.
Crossref Google Scholar
151

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021; 325: 669-85.
Crossref Google Scholar
152

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-49.
Crossref Google Scholar
153

Siegel RL, Medhanie GA, Fedewa SA, Jemal A. State variation in early-onset colorectal cancer in the United States, 1995-2015. J Natl Cancer Inst. 2019; 111: 1104-6.
Crossref Google Scholar
154

Zhang Y, Devocelle A, Souza L, Foudi A, Tenreira Bento S, Desterke C, et al. BMAL1 knockdown triggers different colon carcinoma cell fates by altering the delicate equilibrium between AKT/mTOR and P53/P21 pathways. Aging. 2020; 12: 8067-83.
Crossref Google Scholar
155

Stokes K, Nunes M, Trombley C, Flôres DEFL, Wu G, Taleb Z, et al. The circadian clock gene, Bmal1, regulates intestinal stem cell signaling and represses tumor initiation. Cell Mol Gastroenterol Hepatol. 2021; 12: 1847-72.
Crossref Google Scholar
156

Liu JL, Wang CY, Cheng TY, Rixiati Y, Ji C, Deng M, et al. Circadian clock disruption suppresses PDL1 intraepithelial B cells in experimental colitis and colitis-associated colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021; 12: 251-76.
Crossref Google Scholar
157

Zhang Y, Ma J, Zhang S, Deng G, Wu X, He J, et al. A prognostic analysis of 895 cases of stage Ⅲ colon cancer in different colon subsites. Int J Colorectal Dis. 2015; 30: 1173-83.
Crossref Google Scholar
158

Huisman SA, Oklejewicz M, Ahmadi AR, Tamanini F, Ijzermans JNM, van der Horst GTJ, et al. Colorectal liver metastases with a disrupted circadian rhythm phase shift the peripheral clock in liver and kidney. Int J Cancer. 2015; 136: 1024-32.
Crossref Google Scholar
159

Dong P, Wang Y, Liu Y, Zhu C, Lin J, Qian R, et al. BMAL1 induces colorectal cancer metastasis by stimulating exosome secretion. Mol Biol Rep. 2022; 49: 373-84.
Crossref Google Scholar
160

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7-30.
Crossref Google Scholar
161

Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015; 5: 2929-43.
Google Scholar
162

Xiang S, Mao L, Duplessis T, Yuan L, Dauchy R, Dauchy E, et al. Oscillation of clock and clock controlled genes induced by serum shock in human breast epithelial and breast cancer cells: regulation by melatonin. Breast Cancer (Auckl). 2012; 6: 137-50.
Crossref Google Scholar
163

Rossetti S, Esposito J, Corlazzoli F, Gregorski A, Sacchi N. Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes. Cell Cycle. 2012; 11: 350-60.
Crossref Google Scholar
164

Lesicka M, Jabłońska E, Wieczorek E, Seroczyńska B, Siekierzycka A, Skokowski J, et al. Altered circadian genes expression in breast cancer tissue according to the clinical characteristics. PLoS One. 2018; 13: e0199622.
Crossref Google Scholar
165

Broadberry E, McConnell J, Williams J, Yang N, Zindy E, Leek A, et al. Disrupted circadian clocks and altered tissue mechanics in primary human breast tumours. Breast Cancer Res. 2018; 20: 125.
Crossref Google Scholar
166

Korkmaz T, Aygenli F, Emisoglu H, Ozcelik G, Canturk A, Yilmaz S, et al. Opposite carcinogenic effects of circadian clock gene BMAL1. Sci Rep. 2018; 8: 16023.
Crossref Google Scholar
167

Kwon YJ, Seo EB, Kwon SH, Lee SH, Kim SK, Park SK, et al. Extracellular Acidosis Promotes Metastatic Potency via Decrease of the BMAL1 Circadian Clock Gene in Breast Cancer. Cells. 2020; 9: 989.
Crossref Google Scholar
168

Sharma D, Kumar S, Narasimhan B. Estrogen alpha receptor antagonists for the treatment of breast cancer: a review. Chem Cent J. 2018; 12: 107.
Crossref Google Scholar
169

Xie F, Wang L, Liu Y, Liu Z, Zhang Z, Pei J, et al. ASMT regulates tumor metastasis through the circadian clock system in triplenegative breast cancer. Front Oncol. 2020; 10: 537247.
Crossref Google Scholar
170

Boese AC, Kang S. Tumor progression of breast cancer during hyperinsulinemic obesity. Trends Mol Med. 2020; 26: 354-6.
Crossref Google Scholar
171

Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016; 19: 20-7.
Crossref Google Scholar
172

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677-86.
Crossref Google Scholar
173

Verreck FAW, de Boer T, Langenberg DML, Hoeve MA, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004; 101: 4560-5.
Crossref Google Scholar
174

Qin C, Zhou LQ, Ma XT, Hu ZW, Yang S, Chen M, et al. Dual functions of microglia in ischemic stroke. Neurosci Bull. 2019; 35: 921-33.
Crossref Google Scholar
175

Li X, Guan J, Jiang Z, Cheng S, Hou W, Yao J, et al. Microglial exosome miR-7239-3p promotes glioma progression by regulating circadian genes. Neurosci Bull. 2021; 37: 497-510.
Crossref Google Scholar
176

de Assis LVM, Mendes D, Silva MM, Kinker GS, Pereira-Lima I, Moraes MN, et al. Melanopsin mediates UVA-dependent modulation of proliferation, pigmentation, apoptosis, and molecular clock in normal and malignant melanocytes. Biochim Biophys Acta Mol Cell Res. 2020; 1867: 118789.
Crossref Google Scholar
177

de Assis LVM, Moraes MN, da Silveira Cruz-Machado S, Castrucci AML. The effect of white light on normal and malignant murine melanocytes: a link between opsins, clock genes, and melanogenesis. Biochim Biophys Acta. 2016; 1863: 1119-33.
Crossref Google Scholar
178

Zhanfeng N, Yanhui L, Zhou F, Shaocai H, Guangxing L, Hechun X. Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo. Oncotarget 2015; 6: 9951-8.
Crossref Google Scholar
179

Shen H, Cook K, Gee HE, Hau E. Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in highgrade gliomas. J Exp Clin Cancer Res CR. 2020; 39: 129.
Crossref Google Scholar
180

Wagner PM, Prucca CG, Velazquez FN, Sosa Alderete LG, Caputto BL, Guido ME. Temporal regulation of tumor growth in nocturnal mammals: in vivo studies and chemotherapeutical potential. FASEB J. 2021; 35: e21231.
Crossref Google Scholar
181

Katamune C, Koyanagi S, Hashikawa KI, Kusunose N, Akamine T, Matsunaga N, et al. Mutation of the gene encoding the circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulating the Aldh3a1 gene. J Biol Chem. 2019; 294: 547-58.
Crossref Google Scholar
182

Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400.
Crossref Google Scholar
183

De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; 17: 457-74.
Crossref Google Scholar
184

Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003; 63: 7277-83.
Google Scholar
185

Peek CB, Levine DC, Cedernaes J, Taguchi A, Kobayashi Y, Tsai SJ, et al. Circadian clock interaction with HIF1α mediates oxygenic metabolism and anaerobic glycolysis in skeletal muscle. Cell Metabolism. 2017; 25: 86-92.
Crossref Google Scholar
186

Ma Z, Jin X, Qian Z, Li F, Xu M, Zhang Y, et al. Deletion of clock gene Bmal1 impaired the chondrocyte function due to disruption of the HIF1α-VEGF signaling pathway. Cell Cycle. 2019; 18: 1473-89.
Crossref Google Scholar
187

Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, et al. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/ BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine. 2019; 45: 139-54.
Crossref Google Scholar
188

Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139: 871-90.
Crossref Google Scholar
189

Zhang J, Tian XJ, Xing J. Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks. J Clin Med. 2016; 5: 41.
Crossref Google Scholar
190

Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008; 27: 6920-9.
Crossref Google Scholar
191

Zhang Y, Devocelle A, Desterke C, de Souza LEB, Hadadi É, Acloque H, et al. BMAL1 knockdown leans epithelial-mesenchymal balance toward epithelial properties and decreases the chemoresistance of colon carcinoma cells. Int J Mol Sci. 2021; 22: 5247.
Crossref Google Scholar
192

Slat EA, Sponagel J, Marpegan L, Simon T, Kfoury N, Kim A, et al. Cell-intrinsic, Bmal1-dependent circadian regulation of temozolomide sensitivity in glioblastoma. J Biol Rhythms. 2017; 32: 121-9.
Crossref Google Scholar
193

Wagner PM, Sosa Alderete LG, Gorné LD, Gaveglio V, Salvador G, Pasquaré S, et al. Proliferative glioblastoma cancer cells exhibit persisting temporal control of metabolism and display differential temporal drug susceptibility in chemotherapy. Mol Neurobiol. 2019; 56: 1276-92.
Crossref Google Scholar
194

Jiang W, Zhao S, Shen J, Guo L, Sun Y, Zhu Y, et al. The MiR-135bBMAL1-YY1 loop disturbs pancreatic clockwork to promote tumourigenesis and chemoresistance. Cell Death Dis. 2018; 9: 149.
Crossref Google Scholar
195

Tang Q, Cheng B, Xie M, Chen Y, Zhao J, Zhou X, et al. Circadian clock gene Bmal1 inhibits tumorigenesis and increases paclitaxel sensitivity in tongue squamous cell carcinoma. Cancer Res. 2017; 77: 532-44.
Crossref Google Scholar
196

Trebucq LL, Cardama GA, Lorenzano Menna P, Golombek DA, Chiesa JJ, Marpegan L. Timing of novel drug 1A-116 to circadian rhythms improves therapeutic effects against glioblastoma. Pharmaceutics. 2021; 13: 1091.
Crossref Google Scholar
197

Cardama GA, Gonzalez N, Ciarlantini M, Gandolfi Donadío L, Comin MJ, Alonso DF, et al. Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. OncoTargets and Therapy, 2014; 7: 2021-33.
Crossref Google Scholar
198

Cabrera M, Echeverria E, Lenicov FR, Cardama G, Gonzalez N, Davio C, et al. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget, 2017; 8: 98509-23.
Crossref Google Scholar
199

Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 2010; 8: 23.
Crossref Google Scholar
200

Ridley AJ. Rho GTPase signalling in cell migration. Curr Opin Cell Biol. 2015; 36: 103-12.
Crossref Google Scholar
201

Teixeira AAS, Biondo LA, Silveira LS, Lima EA, Batatinha HA, Diniz TA, et al. Doxorubicin modulated clock genes and cytokines in macrophages extracted from tumor-bearing mice. Cancer Biol Ther. 2020; 21: 344-53.
Crossref Google Scholar
202

Mendes MCS, Pimentel GD, Costa FO, Carvalheira JBC. Molecular and neuroendocrine mechanisms of cancer cachexia. J Endocrinol. 2015; 226: R29-43.
Crossref Google Scholar
203

Kinsey E, Ajazi E, Wang X, Johnston MAM, Crawford J. Predictors of physical and functional loss in advanced-stage lung cancer patients receiving platinum chemotherapy. J Thorac Oncol. 2018; 13: 1294-301.
Crossref Google Scholar
204

Muliawati Y, Haroen H, Rotty LWA. Cancer anorexia - cachexia syndrome. Acta Med Indones. 2012; 44: 154-62.
Google Scholar
205

von Haehling S, Anker SD. Cachexia as major underestimated unmet medical need: facts and numbers. Int J Cardiol. 2012; 161: 121-3.
Crossref Google Scholar
206

Colldén G, Tschöp MH, Müller TD. Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci. 2017; 18: 798.
Crossref Google Scholar
207

Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015; 6: 132-3.
Crossref Google Scholar
208

Hatanaka M, Konishi M, Ishida J, Saito M, Springer J. Novel mechanism of ghrelin therapy for cachexia. J Cachexia Sarcopenia Muscle. 2015; 6: 393.
Crossref Google Scholar
209

Lundholm K, Gunnebo L, Körner U, Iresjö BM, Engström C, Hyltander A, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized doubleblind study. Cancer. 2010; 116: 2044-52.
Crossref Google Scholar
210

Doruk YU, Yarparvar D, Akyel YK, Gul S, Taskin AC, Yilmaz F, et al. A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude. J Biol Chem. 2020; 295: 3518-31.
Crossref Google Scholar
211

Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017; 169: 361-71.
Crossref Google Scholar
212

Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014; 15: 155-62.
Crossref Google Scholar
213

González A, Hall MN. Nutrient sensing and TOR signaling in yeast and mammals. EMBO J. 2017; 36: 397-408.
Crossref Google Scholar
214

Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926-45.
Crossref Google Scholar
215

Matsumoto CS, Almeida LO, Guimarães DM, Martins MD, Papagerakis P, Papagerakis S, et al. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget. 2016; 7: 42393-407.
Crossref Google Scholar
216

Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, et al. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene. 2010; 29: 3881-95.
Crossref Google Scholar
217

Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MCG, et al. PERK is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma. PLoS Genet. 2016; 12: e1006518.
Crossref Google Scholar
218

Bhattacharya S, HuangFu WC, Dong G, Qian J, Baker DP, Karar J, et al. Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene. 2013; 32: 4214-21.
Crossref Google Scholar
219

Lee Y, Fong SY, Shon J, Zhang SL, Brooks R, Lahens NF, et al. Timeof-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle. Sci. Adv. 2021; 7: eabd2645.
Crossref Google Scholar
220

Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015; 33: 3029-35.
Crossref Google Scholar
221

Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, et al. Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Ins. 2012; 104: 749-63.
Crossref Google Scholar
222

Liu HC, Enikolopov G, Chen Y. Cul4B regulates neural progenitor cell growth. BMC Neurosci. 2012; 13: 112.
Crossref Google Scholar
223

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458: 732-6.
Crossref Google Scholar
224

Nawrocki ST, Griffin P, Kelly KR, Carew JS. MLN4924: a novel firstin-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs. 2012; 21: 1563-73.
Crossref Google Scholar
225

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, et al. Pharmacological targeting of miR-155 via the NEDD8- activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 2015; 29: 1981-92.
Crossref Google Scholar
226

Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li C, et al. Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget. 2015; 6: 9002-17.
Crossref Google Scholar
227

Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai YC, et al. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett. 2015; 363: 127-36.
Crossref Google Scholar
228

Zhang S, Zhang J, Deng Z, Liu H, Mao W, Jiang F, et al. Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells. Oncotarget. 2016; 7: 66087-99.
Crossref Google Scholar
229

Yu X, Rollins D, Ruhn KA, Stubblefield JJ, Green CB, Kashiwada M, et al. TH17 cell differentiation is regulated by the circadian clock. Science. 2013; 342: 727-30.
Crossref Google Scholar
230

Hand LE, Gray KJ, Dickson SH, Simpkins DA, Ray DW, Konkel JE, et al. Regulatory T cells confer a circadian signature on inflammatory arthritis. Nat Commun. 2020; 11: 1658.
Crossref Google Scholar
231

Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, et al. Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity. Oncoimmunology. 2016; 5: e1254854.
Crossref Google Scholar
232

Mullins D, Proulx D, Saoudi A, Ng CE. Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity. Int J Radiat Oncol Biol Phys. 2005; 62: 230-7.
Crossref Google Scholar
233

Ozturk N, Ozturk D, Pala-Kara Z, Kaptan E, Sancar-Bas S, Ozsoy N, et al. The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus. Chronobiol Int. 2018; 35: 705-s18.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 20 Issue 1,
January 2023
Pages 1-24
DOI: 10.20892/j.issn.2095-3941.2022.0474
Cite this article:
Huang C, Zhang C, Cao Y, et al. Major roles of the circadian clock in cancer. Cancer Biology & Medicine, 2023, 20(1): 1-24. https://doi.org/10.20892/j.issn.2095-3941.2022.0474

119

Views

4

Downloads

18

Crossref

14

Web of Science

15

Scopus

Altmetrics
Received: 08 August 2022
Accepted: 04 November 2022
Published: 12 January 2023
©2023 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return